Clinical trials
Peripheral Arterial Disease trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
47 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 3 |
| 2007 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 25 |
| Recruiting | 7 |
| Unknown status | 6 |
| Active, not recruiting | 5 |
| Terminated | 4 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Radboud University Medical Center | 3 |
| AstraZeneca | 2 |
| Bayer | 2 |
| Biotronik AG | 2 |
| CSL Behring | 2 |
| Catharina Ziekenhuis Eindhoven | 2 |
| Eli Lilly and Company | 2 |
| M.A. Med Alliance S.A. | 2 |
| UMC Utrecht | 2 |
| W.L.Gore & Associates | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peripheral Arterial Disease | 47 |
| Atherosclerosis | 8 |
| Cardiovascular Diseases | 8 |
| Coronary Artery Disease | 6 |
| Chronic Limb-Threatening Ischemia | 4 |
| Intermittent Claudication | 4 |
| Myocardial Infarction | 4 |
| Stroke | 4 |
| Diabetes Mellitus, Type 2 | 3 |
| Heart Diseases | 3 |
Trials
Showing 51 to 47 of 47. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.